MHRA: Opens Call for AI Airlock Phase 3 Applications

• The UK government fully accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare on October 6, 2026.
• The MHRA has opened applications for Phase 3 of its AI Airlock regulatory sandbox, focusing on post-market surveillance for AI medical devices.
• This initiative aims to establish a lifecycle-based regulatory framework for AI, moving beyond one-time assessments.
• The MHRA will issue draft guidance on managing changes to AI devices by December 2026 and consult on classification next year.
• A full implementation roadmap for all recommendations is expected by Spring 2027, outlining timelines and responsibilities.

The government's response explicitly commits the UK to developing this agile regulatory system, ensuring that patients can access safe, effective, and trusted AI solutions more rapidly, supported by robust safeguards that adapt as the technologies advance.

On October 6, 2026, the UK government officially announced its full acceptance of all 44 recommendations put forth by the National Commission into the Regulation of AI in Healthcare. These recommendations, originally published on September 10, outline a comprehensive strategy for integrating artificial intelligence safely and effectively into the healthcare system across the entire United Kingdom. This endorsement signals a significant shift in the UK government AI healthcare policy, aiming to establish a world-leading, agile regulatory framework for AI-enabled medical devices.

Concurrently with this announcement, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated the call for MHRA AI Airlock Phase 3 applications. This phase of the regulatory sandbox for AI medical devices is directly informed by the National Commission AI Healthcare recommendations, particularly focusing on the critical area of post-market surveillance. The government's commitment underscores a move towards a more dynamic and responsive regulatory environment designed to foster innovation while rigorously upholding patient safety and public trust.

A core tenet of the National Commission's findings was the necessity for the existing UK AI medical device regulation to evolve beyond traditional, one-time assessments. The Commission advocated for a proportionate, lifecycle-based framework that continuously evaluates AI technologies throughout their operational lifespan. This approach aims to provide a more accurate understanding of true device performance in real-world settings, moving away from an over-reliance on initial approvals. The government's response explicitly commits the UK to developing this agile regulatory system, ensuring that patients can access safe, effective, and trusted AI solutions more rapidly, supported by robust safeguards that adapt as the technologies advance.

As part of the initial steps to implement these reforms, the MHRA has committed to releasing MHRA draft guidance AI medical devices by December 2026. This guidance will specifically address a new methodology for managing changes to AI-enabled medical devices as they undergo updates and improvements over time. Furthermore, early next year, the MHRA will commence consultations on the qualification and classification of AI-enabled devices, directly addressing the first recommendation from the National Commission. These actions are pivotal in shaping a regulatory landscape that supports timely access to innovative devices while maintaining stringent safety standards.

The MHRA AI Airlock Phase 3 applications represent an immediate practical implementation of the Commission's emphasis on continuous monitoring. This phase of the AI medical device regulatory sandbox UK is specifically designed to test how AI devices can be safely overseen and managed for post-market surveillance once they are deployed in clinical settings. Developers of eligible AI-enabled medical devices are encouraged to apply, with a webinar scheduled for October 22 to provide further details to prospective participants. The program, which has secured three years of additional government funding following successful pilot and Phase 2 programs, will generate crucial insights, evidence, and solutions that will directly inform future MHRA guidance and policy regarding AI medical device regulation.

The focus of this phase is squarely on lifecycle regulation and MHRA AI post-market surveillance, reflecting the central themes of the Commission's recommendations. By collaborating with developers, regulators, and healthcare partners, the Airlock aims to build a robust framework for ongoing assessment, ensuring that the performance and safety of AI medical devices are understood and managed throughout their entire working life. This initiative is critical for building public confidence and enabling the responsible adoption of AI in healthcare.

Beyond the immediate regulatory adjustments, the government's comprehensive plan includes exploring new staged authorisation pathways. These pathways are intended to allow promising AI tools to be introduced into the National Health Service (NHS) earlier, under close supervision, while additional real-world evidence is systematically gathered. This progressive approach aims to accelerate the benefits of AI for patients without compromising safety.

A detailed implementation roadmap, outlining specific timelines and responsibilities for all 44 recommendations, is slated for publication by Spring 2027, with regular progress updates to follow. The UK government AI healthcare policy also extends to broader societal considerations, including commitments to enhance patient engagement in decision-making processes, improve access to redress mechanisms for substandard care, and ensure that the benefits derived from AI are distributed equitably across all communities, particularly those currently underserved. This holistic strategy underscores a long-term vision for AI integration in healthcare that balances innovation with ethical and social responsibility.

Lawyers advising clients in the AI medical device sector should note the UK government's commitment to a new, lifecycle-based regulatory framework. Specifically, they should inform clients about the immediate opportunity to apply for MHRA's AI Airlock Phase 3 to test post-market surveillance of AI-enabled medical devices, and prepare for upcoming draft guidance on managing device changes and classification.

Source: Original reporting via GOV.UK announcement